One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, surgical robots, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Last trade$102.95
Day change+$0.07 (+0.07%)
Day range$102.37 – $103.79
Volume2,753,259
Market cap$131.60B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$131.6B
Price / earnings
25.16×
Price / book
2.62×
Price / sales
3.51×
EV / sales
4.21×
EV / EBITDA
15.74×
Profitability
Earnings per share
$4.09
Return on assets
5.61%
Return on equity
10.41%
Dividend yield
2.77%
Liquidity and leverage
Debt / equity
0.56×
Current ratio
2.07×
Quick ratio
1.54×
Cash ratio
0.14×
Cash flow
Price / cash flow
16.38×
Price / free cash flow
21.46×
Free cash flow
$6.13B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MDT, quarterly periods
Line item
Q1 FY2027 Jul 31, 2026
Q4 FY2026 Apr 24, 2026
Q3 FY2026 Jan 23, 2026
Q2 FY2026 Oct 24, 2025
Q1 FY2026 Jul 25, 2025
Q4 FY2025 Apr 25, 2025
Q3 FY2025 Jan 24, 2025
Q2 FY2025 Oct 25, 2024
Revenue
$9.76B
$9.81B
$9.02B
$8.96B
$8.58B
$8.93B
$8.29B
$8.4B
Cost of revenue
$3.42B
$3.4B
$3.26B
$3.06B
$3B
$3.15B
$2.78B
$2.95B
Gross profit
$6.34B
$6.41B
$5.76B
$5.9B
$5.58B
$5.78B
$5.51B
$5.46B
Selling, general and administrative
$3.2B
$3.06B
$2.96B
$2.97B
$2.81B
$2.72B
$2.72B
$2.76B
Research and development
$771M
$671M
$722M
$754M
$726M
$684M
$675M
$697M
Total operating expenses
$4.58B
$4.66B
$4.26B
$4.19B
$4.13B
$4.31B
$3.87B
$3.9B
Operating income
$1.76B
$1.75B
$1.5B
$1.71B
$1.44B
$1.47B
$1.64B
$1.56B
Interest expense
-$186M
-$176M
-$181M
-$181M
-$176M
-$174M
-$179M
-$209M
Income before taxes
$1.77B
$1.83B
$1.4B
$1.6B
$1.3B
$1.26B
$1.54B
$1.56B
Income taxes
$289M
$575M
$254M
$215M
$255M
$199M
$237M
$281M
Net income
$1.48B
$1.26B
$1.15B
$1.38B
$1.05B
$1.06B
$1.3B
$1.28B
Net income attributable to common shareholders
$1.47B
$1.24B
$1.14B
$1.37B
$1.04B
$1.06B
$1.29B
$1.27B
EBITDA
$2.57B
$2.69B
$2.32B
$2.46B
$2.26B
$2.78B
$2.37B
$2.27B
Basic earnings per share
$1.15
$0.97
$0.89
$1.07
$0.81
$0.82
$1.01
$0.99
Diluted earnings per share
$1.14
$0.97
$0.89
$1.07
$0.81
$0.82
$1.01
$0.99
Recent news
Company coverage with links to the original publishers.
The global nerve repair and regeneration market is projected to grow from USD 10.65 billion in 2025 to USD 20.97 billion by 2031, expanding at an 11.96% CAGR. Growth is driven by rising nerve injuries, advances in neurostimulation technologies, and biomaterial innovations. Neurostimulation devices currently dominate with 58.74% market share, while biomaterials are the fastest-growing segment at 14.01% CAGR. High implant costs and cybersecurity risks remain challenges, with Asia-Pacific expected to record the fastest regional growth.
Intuitive Surgical delivered robust Q3 2026 results with adjusted EPS up 25% to $3 and revenue growth of 22% to $3.1 billion, driven by expanding robotic platform adoption and improved operating efficiency. The company maintains a 42% operating margin while investing heavily in R&D for AI features and new platforms. However, reported GAAP net income declined due to a $450 million litigation settlement. Peer medical device makers Stryker and Medtronic also posted strong earnings growth, though facing headwinds from procedure volume pressures and supply constraints.
Medtronic is expected to report Q2 fiscal 2027 results on November 24, with revenues projected to grow 5.7% to $9.47 billion and EPS estimated at $1.34 (down 1.5% YoY). The Cardiovascular segment is expected to drive growth at 9.6%, supported by cardiac ablation, CRM, and structural heart products. Diabetes revenues are projected to grow 12.9% following the MiniMed separation. However, the company has a negative Earnings ESP of -0.75%, suggesting limited upside surprise potential.
FitLife Brands reported quarterly earnings of $0.19 per share, missing the consensus estimate of $0.25 and representing a -24% earnings surprise. Revenue also fell short of expectations at $25.62 million versus the estimate. The stock has significantly underperformed the market, declining 47.9% year-to-date compared to the S&P 500's 10.5% gain. With a Zacks Rank #3 (Hold) rating and the Medical-Products industry in the bottom 43% of performance, the outlook remains uncertain pending management commentary.
The article recommends five dividend stocks suitable for long-term buy-and-hold investors: Johnson & Johnson, Medtronic, Procter & Gamble, Federal Realty Investment Trust, and Realty Income. All five companies have strong dividend track records with at least 32 years of consecutive annual increases, combined with well-run underlying businesses that generate reliable income streams.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Sep 25, 2026
$0.72
Oct 16, 2026
recurring
Jun 26, 2026
$0.72
Jul 17, 2026
recurring
Mar 27, 2026
$0.71
Apr 17, 2026
recurring
Dec 26, 2025
$0.71
Jan 16, 2026
recurring
Sep 26, 2025
$0.71
Oct 17, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.